Background Schizophrenia is a common and burdensome illness, with implications not only for the health service but for a host of other care agencies - public and private - as well as for patients, families and the wider society.
Method The paper reviews available UK evidence on the cost of schizophrenia (broadly defined) and on the cost-effectiveness oftreatment options and alternative care arrangements.
New evidence potentially alters our view of the costs ofthis illness.
Results Aggregating the identifiable direct and indirect costs of schizophrenia for England suggests an annual cost of £2.6 billion, but even this sum omits some indirect impacts which cannot currently be costed.
Just over halfthe identified total is accounted for by the direct costs falling to the NHS, local authorities, charities and the cr minal justice system.
In helping to tackle this cost burden, there is now a body of evidence on cost-effective community care arrangements, antipsychotic drugs and psychological nterventions.
Conclusions Although the costs of schizophrenia are considerable, there are treatments and care arrangements which can reduce th aggregate burden while maintaining or improving effectiveness.
Mots-clés Pascal : Schizophrénie, Analyse coût, Economie santé, Royaume Uni, Europe, Article synthèse, Homme, Psychose
Mots-clés Pascal anglais : Schizophrenia, Cost analysis, Health economy, United Kingdom, Europe, Review, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0039526
Code Inist : 002B18C06B. Création : 17/04/1998.